Blog

Photo from Mel Mann/LinkedIn

May 11, 2024, 02:47

Mel Mann: Gleevec’s Anniversary

Mel Mann, Patient Advocate in

”Gleevec’s Anniversary.

On 10 May 2001, Gleevec (Imatinib) was approved by the FDA for use in Chronic Myeloid Leukemia (CML) and made the cover of TIME Magazine. It now works for 11 different types of cancer.

I was blessed to enter the Gleevec phase 1 clinical trial when it began 3 years prior, in 1998, and I became the World’s Longest Living Gleevec Survivor. When I was first diagnosed, I was given 3 years to live. However, I was able to get ‘Today’s medicine Yesterday,’ and that 3 years became 30 years. Clinical Trials are a way of getting ‘Tomorrow’s Medicine Today.”’

Mel Mann

Source: Mel Mann/LinkedIn

cancer chronic myeloid leukemia clinical trial CML FDA Gleevec imatinib Mel Mann OncoDaily Oncology Time magazine World’s Longest Living Gleevec Survivor

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage